RCTJadad 3/5RandomizedDouble-BlindPlacebo-Controlled

3 Days, Not 5 Weeks: What a New Crossover Trial Says About Fast-Acting Creatine

Journal of the International Society of Sports NutritionJanuary 24, 2026Vol. 22 (Suppl 1)

Summary

If you lift weights and have ever wondered whether you need to "load" creatine for a month before it does anything, this new study offers a more practical answer: even a 3-day creatine protocol can meaningfully boost strength and speed up recovery — as long as you time the first dose right.

Published in the Journal of the International Society of Sports Nutrition (Jan 2026), this small but tightly controlled trial recruited 11 young, creatine-naïve, recreationally resistance-trained men (10 completed) in Tunisia. It used a double-blind, placebo-controlled crossover design — meaning each participant tried both creatine monohydrate (CrM) and a taste-matched placebo, in random order, with a 7-day washout between them. That's a strong design for teasing out a true drug/supplement effect, even with a small sample.

The protocol was unusual: 0.3 g per kg of bodyweight (roughly 21–24g for a 70–80kg person) taken as a single dose two hours before the first training session, then split into three smaller daily doses (0.1 g/kg each) over the following two days — a mini-loading phase rather than the classic 5-day, 20g/day protocol or the slow 3g/day-for-a-month approach.

The results were striking for such a short window. Compared to placebo, creatine users completed significantly more reps to failure at 60–80% of their one-rep max (1RM) on bench press and back squat (effect sizes d=0.75–1.6), lifted with higher bar velocity and power across nearly every load tested (some effect sizes exceeding d=3, which is enormous by exercise-science standards), and showed lower cardiovascular strain (lower peak heart rate) at moderate intensity. Recovery markers also favored creatine: jump performance (countermovement jump) was better preserved 24–48 hours after training, muscle soreness (DOMS) in both arms and legs was lower heading into the second session, and heart-rate-variability markers linked to parasympathetic ("rest and recover") nervous system activity improved after the first session — though that recovery-nervous-system benefit faded by the second session, likely due to accumulating fatigue.

Blinding worked well (only 55% correctly guessed which supplement they got — no better than chance), and there were no reported adverse events, consistent with creatine's decades-long safety record.

The bottom line: this adds to growing evidence that creatine doesn't require a long lead-in to work. A short, front-loaded dose before your next session might give a noticeable performance and recovery edge — useful for athletes with an upcoming competition, photoshoot, or busy training block who don't have weeks to plan ahead.

What This Means For You

This study supports a practical "just-in-time" creatine strategy, distinct from the two commonly marketed approaches: (1) the classic 20g/day for 5 days loading phase, or (2) the slow-and-steady 3–5g/day for 3–4 weeks. Here, participants took roughly 0.3g per kg of bodyweight as a single dose 2 hours pre-workout, then 0.1g/kg three times daily for two more days — a compressed 3-day protocol.

Who might benefit most: recreational lifters or athletes who didn't plan ahead and want a performance boost before a specific session, competition, or short training block, particularly for compound lifts (squat, bench) performed at 60–80% 1RM for reps.

Dosage takeaway: for a 75kg (165lb) person, that's about 22.5g on day one (in three divided doses if preferred, though the study used one big dose) and roughly 7.5g x3/day on days two and three — notably higher than the standard 3–5g maintenance dose, so this is a short, aggressive front-load, not a everyday regimen. Standard creatine monohydrate powder (unflavored, third-party tested, e.g. NSF Certified for Sport or Informed-Sport labeled) is the best-studied and cheapest form — there's no evidence more expensive forms (HCl, buffered, etc.) outperform monohydrate.

Timing: taking the first full dose ~2 hours before training, with water, appeared effective here — but note this study did not compare timing conditions head-to-head.

For recovery and DOMS reduction, this adds to evidence that creatine may modestly blunt next-day soreness and preserve explosive power (jump height) — relevant for anyone training the same muscle groups again within a week.

Caution: this was a short 3-day exposure in creatine-naïve men; those already taking creatine won't see the same "acute" boost since their stores are likely already saturated. Athletes with kidney or liver conditions should still consult a physician before any high-dose creatine loading.

Important Considerations

This was a small pilot (10 analyzed participants, all young, healthy, recreationally trained men in Tunisia) — results may not generalize to women, older adults, highly trained/elite athletes, or people with different training histories. No women were included specifically to avoid menstrual-cycle-related confounds, so sex-specific effects remain unknown and are an active area of separate research.

The 7-day washout between creatine and placebo phases is shorter than the 4–6 weeks typically needed for intramuscular creatine to fully return to baseline, so some carryover effect into the "placebo" condition can't be completely ruled out, even though baseline measures looked similar across sessions.

The dosing protocol (0.3g/kg front-loaded, then divided) is not what's found on most commercial supplement labels, which usually recommend a flat 5g/day or a 20g/day x5-day loading phase — so this isn't a direct comparison to how most people currently use creatine.

No biochemical markers (creatine kinase, oxidative stress markers) were measured, so the mechanisms behind reduced soreness and improved HRV remain inferred rather than confirmed. Many outcomes were secondary/exploratory with multiple comparisons, and while Bonferroni correction was applied, the small sample size means individual results should be interpreted cautiously rather than as definitive.

As with any supplement study, be skeptical of marketing claims that cite "3-day results" as proof creatine works instantly for everyone — this was one narrow protocol in a narrow population. Long-term creatine safety and efficacy (weeks to years) is separately well-established by much larger bodies of research; this study speaks only to short-term/acute effects. Anyone with pre-existing kidney or liver issues should talk to a doctor before high-dose creatine loading.

Terms Explained

Creatine monohydrate (CrM)The most-studied, cheapest, and best-absorbed form of creatine supplement, used to increase muscle phosphocreatine stores for quick energy during high-intensity exercise.

1RM (One-Rep Max)The maximum weight a person can lift for a single repetition of an exercise; used to set training intensities as a percentage (e.g. 70% 1RM).

Loading phaseA short period of higher-than-normal creatine intake (often 20g/day for 5 days) designed to rapidly saturate muscle creatine stores, versus a slower steady daily dose.

Crossover trialA study design where every participant receives both the treatment and the placebo, in random order with a washout period between, allowing each person to serve as their own control.

Double-blindNeither participants nor researchers know who received the real supplement versus the placebo, reducing bias in reported results.

DOMS (Delayed Onset Muscle Soreness)The muscle soreness and stiffness that typically peaks 24–72 hours after unfamiliar or intense exercise.

Heart Rate Variability (HRV)The variation in time between heartbeats, used as a non-invasive marker of nervous system recovery and readiness to train — higher parasympathetic activity generally signals better recovery.

Countermovement Jump (CMJ)A vertical jump test where the person dips down before jumping, used to measure explosive lower-body power and neuromuscular fatigue.

Phosphocreatine (PCr)A high-energy molecule stored in muscle that rapidly regenerates ATP during short, intense bursts of effort like heavy lifting or sprinting.

Effect size (Cohen's d)A statistic showing how large a difference is between two groups, independent of sample size; values above 0.8 are generally considered large.

Washout periodA gap between treatment phases in a crossover study, meant to let effects of the first treatment fade before starting the next one.

Technical Study Details

Study Design

RegistrationPan African Clinical Trials Registry: PACTR202505827886996

Total Score

JADAD Quality Assessment

/ 5

評価詳細

Randomization

0 / 2

Is the study described as randomized?

Yes+1

Rationale: The article explicitly and repeatedly describes itself as "randomized"/"randomised" in the abstract, introduction, and methods sections, including describing the crossover design and the randomized order of test sessions.

Is the method of randomization described and appropriate?

No-1

Rationale: The article repeatedly states that the study was randomized (e.g., "randomized order," "double-blind, crossover, randomised controlled design") and specifies that "two independent individuals handled randomisation and kit preparation." However, nowhere does the text describe the actual method used to generate the randomization sequence (e.g., computer-generated random numbers, random number table, coin toss). Since randomization is mentioned but the specific method is not described, per Jadad scale scoring this criterion should be answered "no."

Blinding

2 / 2

Is the study described as double-blind?

Yes+1

Rationale: The article explicitly and repeatedly describes the study design as "double-blind" in the abstract, introduction, and methods sections (Experimentation protocol).

Is the method of blinding described and appropriate?

Yes+1

Rationale: The article explicitly describes the blinding method: CrM was mixed with placebo juice to ensure identical colour, texture, and appearance, kits were prepared by independent individuals not involved in data collection, and researchers remained blinded until study completion. This is an appropriate double-blinding method. Additionally, blinding efficacy was empirically verified via a post-study guess test showing accuracy near chance level, further supporting that the blinding method was appropriate and effective.</rationale> </invoke>

Dropouts/Withdrawals

1 / 1

Is there a description of dropouts and withdrawals?

Yes+1

Rationale: The article reports the initial number recruited (eleven) versus the number analyzed (ten), explicitly stating that one participant was excluded and giving the reason ("due to incomplete data"). This satisfies the Jadad Q5 criterion of describing the number and reason for withdrawal, since the crossover design means all participants were in both conditions, so this single reported exclusion accounts for withdrawals across the whole study.

Study Population

Sample Size11

Age Range19-24 years

ConditionRecreationally resistance-trained, physically active males

Inclusion Criteria

Structured resistance training ≥3 times per week for ≥6 weeks
Familiar with bench press and back squat exercises
Creatine-supplementation naïve at baseline

Interventions

Creatine monohydrate (CrM)

Treatment

Dose0.3 g·kg−1·d−1 (day 1: full dose 2 h pre-test; days 2–3: divided into three sub-doses of 0.1 g·kg−1·d−1)

FrequencyOnce on day 1 (pre-test); three times daily on days 2–3

Duration3 days

Routeoral

Placebo (PLA)

Control

FrequencySame schedule as CrM condition

Duration3 days

Routeoral

Outcomes

Outcome	Type	Effect	p-value
Total load lifted (kg) - Back Squat	Primary	-	-
Repetitions completed to failure - Bench Press	Secondary	1.25	p=0.0034Significant
Repetitions completed to failure - Back Squat	Secondary	0.79	p=0.036Significant
Maximum velocity - Bench Press	Secondary	1.11	p=0.007Significant
Maximum velocity - Back Squat	Secondary	2.83	p=0.001Significant
Maximum power - Bench Press	Secondary	-	-
Maximum power - Back Squat	Secondary	-	-
Peak heart rate - Bench Press	Secondary	-	-
Peak heart rate - Back Squat	Secondary	1.05	p=0.017Significant
∆Pre-Post change in Mean RR interval	Secondary	-	p=0.821
∆Pre-Post change in RMSSD	Secondary	2.99	p=0.015Significant
∆Pre-Post change in SDNN	Secondary	-	p=0.539
∆Pre-Post change in LF power	Secondary	-	p=0.07
∆Pre-Post change in HF power	Secondary	2.76	p=0.022Significant
∆Pre-Post change in blood lactate	Secondary	-	p=0.068
Countermovement Jump performance	Secondary	1.10	p=0.006Significant
Squat Jump performance	Secondary	-	p=0.845
Delayed Onset Muscle Soreness - upper limb (elbow flexors)	Secondary	1.15	p=0.012Significant
Delayed Onset Muscle Soreness - lower limb (knee extensors)	Secondary	1.04	p=0.01Significant

Safety

Dropout Rate9.1%

Conclusion

A 3-day creatine monohydrate supplementation protocol (initial full dose taken pre-training, followed by divided daily doses) enhanced strength performance and neuromuscular recovery in resistance-trained males, improving repetitions, peak velocity, and power during bench press and back squat at 60–80% 1RM. CrM also reduced post-session heart rate at certain intensities, reduced muscle soreness (24–48h), preserved countermovement jump performance, and improved HRV parasympathetic indices (RMSSD, HF) after the first session. These findings suggest acute ingestion followed by short-term CrM use is an effective ergogenic strategy for athletes training multiple times weekly, though effects on HRV and some outcomes attenuated by the second session, likely due to accumulated fatigue.

Limitations

The trial was designed to evaluate only acute and short-term effects; conclusions about long-term adaptations are outside its scope.
The homogeneous sample (young, recreationally resistance-trained males, n=10) limits external validity and generalisability to other populations.
The seven-day washout period between conditions may not have allowed complete normalisation of intramuscular creatine, which typically requires four to six weeks after cessation, though baseline HRV, performance, and lactate measures were comparable across sessions.
Only male participants were enrolled to avoid menstrual-cycle-related variability, limiting applicability to females; cycle-phase-controlled studies were beyond the scope of this pilot.
Biochemical markers of muscle damage and oxidative stress (e.g. creatine kinase, lipid peroxidation) were not measured alongside strength and HRV outcomes.
Dietary confounding was minimised by instruction only (avoiding creatine-rich foods and supplements) rather than detailed diet logs or biomarkers of adherence.